AB Science S.A. (the “ Company ” or “ AB Science ”, Euronext – FR0010557264 – AB) today announces the settlement and delivery of its capital increase announced on May 20, 2025 for an amount of €1.8 ...

On January 29, 2025, Inventiva announced the publication in Journal of Hepatology of the results of the investigator-initiated proof-of-concept clinical trial led by Dr. Kenneth Cusi, demonstrating ...

The strategic collaboration with Broad Clinical Labs will explore and develop applications using Roche’s SBX sequencing technology1, with an initial focus on critically ill newborns and their parents.

Founded in Granbury, Texas, Revolver Brewing has built its reputation on pushing boundaries while staying true to its roots.

Updated data from the pivotal phase III STARGLO study continue to demonstrate a clinically meaningful improvement in overall survival with a Basel, 23 May 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) ...

Jefferies is acting as lead book-running manager for the offering and H.C. Wainwright & Co. is acting as co-manager for the offering. Gyre intends to use the net proceeds from this offering, together ...

Updated results of fruquintinib combined with PD-1 inhibitors and chemotherapy in the first-line treatment of HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma (FDZL-FIX): a ...

NIC is a Canadian company which has the exclusive master franchise rights from NoBrainer Alzheimer’s Treatment Centers, Inc. (“NATC”) for the Canadian market (with the exception of the cities of ...

Conference: LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar Date/Time: Thursday, May 29 th at 2:40 PM ET Presenter: Timothy Lu, M.D., Ph.D. Co-Founder and Chief Executive ...

Serina also announced the departure of Remy Gross from its Board of Directors. Mr. Ledger stated, “Remy has been a trusted advisor to the team at Serina for many years. We thank Remy for his ...

Endurance Bio Inc., a clinical-stage biotechnology company developing therapies for neurodegenerative and metabolic diseases, today announced that its compound, T-168, has been selected for testing on ...

Clinical validation of the Azymetric platform is demonstrated by the accelerated approval our partner Jazz Pharmaceuticals received from the U.S. Food and Drug Administration in 2024 for Ziihera® ...